FDA approves betrixaban for VTE prophylaxis


Betrixaban, a factor Xa inhibitor, has been approved for the prophylaxis of venous thromboembolism (VTE) in at-risk adult patients hospitalized with an acute illness, according to an announcement from the Food and Drug Administration.

Approval was based on results from a randomized, double-blind clinical trial in which over 7,000 hospitalized patients at risk for VTE received either extended-duration betrixaban (35-42 days) or short duration enoxaparin (6-14 days), a low molecular weight heparin administered subcutaneously. The rate of deep vein thrombosis, nonfatal pulmonary embolism, or VTE-related death was 4.4% among patients receiving betrixaban and 6% among patients receiving enoxaparin (relative risk, 0.75; 95% confidence interval: 0.61, 0.91).

FDA icon Courtesy Wikimedia Commons/FitzColinGerald/Creative Commons License
A total of 54% of patients receiving betrixaban had at least one adverse event, compared with 52% of patients receiving enoxaparin. The incidence of serious adverse events was also similar for both groups at 18% among betrixaban-treated patients and 17% among enoxaparin-treated patients. The most common adverse events were related to bleeding (2.4% for betrixaban and 1.2% for enoxaparin), which was also the most common reason for treatment discontinuation in both groups.

The recommended dosage for betrixaban is 80 mg per day for 35-42 days at the same time every day with food, after a dose of 160 mg on the first day of treatment.

Betrixaban will be marketed as Bevyxxa by Portola.

Find the full FDA announcement and prescribing information on the FDA website.

Recommended Reading

   Comments ()